he purpose of this study is to determine the efficacy and safety of remote ischemic conditioning for acute ischemic stroke.
In this study, 912 cases of ischemic stroke in 48 hours were included in 5 centers in China according to the principle of random, double-blind and parallel control .The experimental group receive basic treatment and remote ischemic conditioning for 200mmHg, 2 times per day for 7 consecutive days .The control group receive basic treatment and remote ischemic conditioning control for 60mmHg, 2 times per day, 7 days in a row . Two groups will be followed up for 90 days to evaluate the efficacy and safety of remote ischemic conditioning therapy.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
912
Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mm Hg. RIC will be conducted twice daily for 7 days.
Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 60 mm Hg. RIC will be conducted twice daily for 7 days.
First Hospital of Jilin University
Changchun, Jilin, China
Proportion of patients with Modified Rankin Scale (mRS) Score 0-2
The primary outcome measure of efficacy is the modified Rankin Scale (mRS) dichotomized to define good functional outcome as mRS 0-2 at 90 days.score, dichotomized to define good functional outcome as mRS 0-2 at 90 days.
Time frame: 3 months
NIHSS Score at end of 7th day of treatment
NIHSS Score at end of 7th day of treatment
Time frame: 7 days
mRS Score at end of 7th day of treatment
mRS Score at end of 7th day of treatment
Time frame: 7 days
Barthel Index at end of 7th day of treatment
Barthel Index at end of 7th day of treatment
Time frame: 7 days
Changes of hematological indicators
The changes of hematological indicators (inflammatory cytokine,et al.) between the first 48h and end of 7th day of treatment.
Time frame: 48h; 7days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.